In the Netherlands, new cases of Parkinson’s disease occur more often in men, older adults, people with higher socioeconomic status, and residents of the northern provinces, suggesting that long-term environmental factors may contribute to the disease, according to a study from Utrecht University. According to a university press…
News
Mair Therapeutics is collaborating with Radboud University in the Netherlands to advance Parkinson’s disease research by developing small molecules designed to target TMEM175, a protein that genetic studies have linked to Parkinson’s risk. “Parkinson’s disease remains one of the most pressing medical challenges of our time,” Vasily Kazey, PhD,…
Michael J. Fox is returning to the small screen for season three of Apple TV+’s “Shrinking.” Once again, he is using his craft to elevate awareness and understanding of Parkinson’s disease. For the actor and advocate, the role is a continuation of a mission that has shaped his life…
People with Parkinson’s disease may show subtle changes in their driving abilities even when standard cognitive tests appear normal, according to a study that used a driving simulator to detect impairments. The simulator revealed slower reaction times and reduced control of lane position — an indicator of impaired visuospatial…
In-home caregiving service provider Comforcare announced a specialized program to support people living with Parkinson’s disease and their caregivers. The Parkinson’s Pathway Program is designed to improve patients’ quality of life by providing trained caregivers to help with medication management, movement and exercise, nutrition, and emotional support. “Parkinson’s disease…
A clinical trial testing Teitur Trophics‘ TT-P34 in Parkinson’s disease will use Neuralight‘s brain function biomarker based on eye movement to assess neural circuitry, the companies announced. Neuralight’s platform provides precise measures of brain function derived from eye movements, based on well-established links between specific eye movement…
A team at Michigan State University (MSU) won two grants to support research into portable devices designed to improve communication for people with Parkinson’s disease and atypical parkinsonism. Thea Knowles, PhD, assistant professor in MSU’s Department of Communicative Sciences and Disorders, is leading a team investigating the devices’ effectiveness at…
Light therapy using Celeste, Photopharmics’ investigational photo-neuromodulation device, was seen in a clinical trial to ease nonmotor symptoms in people with Parkinson’s disease, and to also improve quality of life for patients. Treatment also showed a trend toward reduced motor symptoms, the study’s main goal, although this effect…
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to NouvNeu001, iRegene Therapeutics’ cell therapy for Parkinson’s disease. The FDA based its decision on data from a Phase 1/2 trial (NCT06167681) in China, which showed that the treatment eased motor symptoms in Parkinson’s…
BT-267, an LRRK2 inhibitor being developed by Brenig Therapeutics as a treatment for Parkinson’s disease, has reached sustained, clinically meaningful levels in the brain, according to early results from a study in healthy volunteers. The therapy is being developed for both idiopathic Parkinson’s, where the cause is…
Recent Posts
- Camping can be a wonderful activity for those of us living with Parkinson’s
- Immunis plans Phase 1 trial of treatment for Parkinson’s dyskinesia
- MJFF grants $6.9M to prepare OPM’s Parkinson’s therapy for clinical trial
- The invisible support a Parkinson’s caregiver provides
- US, China regulators OK trials of stem cell therapy in MSA-P